Erythropoietin: The swinging pendulum

Leukemia Research

Volumn 36, Issue 8, 2012, Pages 939-944

  Oster, Howard S ^a,b   Neumann, Drorit ^b   Hoffman, Michael ^a,b   Mittelman, Moshe ^a,b  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Cancer; Erythropoiesis stimulating agents (ESAs); Erythropoietin; Mortality; Quality of life; Survival

Indexed keywords

ERYTHROPOIETIN; ERYTHROPOIETIN ALPHA; ERYTHROPOIETIN BETA; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

ANEMIA; BLOOD TRANSFUSION; BREAST CANCER; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL PRACTICE; DISEASE FREE SURVIVAL; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HEAD AND NECK CANCER; HUMAN; LUNG CANCER; LYMPHOPROLIFERATIVE DISEASE; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; REVIEW; RISK FACTOR; SURVIVAL RATE; TREATMENT RESPONSE; UTERINE CERVIX CANCER;

ANEMIA; CLINICAL TRIALS AS TOPIC; ERYTHROPOIETIN; HEMATINICS; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; SOCIETIES, MEDICAL; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84862524935     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.04.017     Document Type: Review

References (55)

1. Mittelman M. The myelodysplastic syndromes-1990. Isr J Med Sci 1990, 26(8):468-478.
2. Mittelman M. Recombinant erythropoietin in myelodysplastic syndromes: whom to treat and how? More questions than answers. Acta Haematol 1993, 90(2):53-57.
3. Eschbach J.W., Kelly M.R., Haley N.R., Abels R.I., Adamson J.W. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med 1989, 321(3):158-163.
4. Mittelman M., Zeidman A., Fradin Z., Magazanik A., Lewinski U.H., Cohen A. Recombinant human erythropoietin in the treatment of multiple myeloma-associated anemia. Acta Haematol 1997, 98(4):204-210.
5. Spivak J.L. Recombinant human erythropoietin and the anemia of cancer. Blood 1994, 84(4):997-1004.
6. Ludwig H., Sundal E., Pecherstorfer M., et al. Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy. Cancer 1995, 76(11):2319-2329.
7. Leyland-Jones B. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003, 4(8):459-460.
8. Leyland-Jones B., Semiglazov V., Pawlicki M., et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005, 23(25):5960-5972.
9. Aapro M., Spivak J.L. Update on erythropoiesis-stimulating agents and clinical trials in oncology. Oncologist 2009, 14(Suppl. 1):6-15.
10. Henke M., Laszig R., Rube C., et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003, 362(9392):1255-1260.
11. Leyland-Jones B., Mahmud S. Erythropoietin to treat anaemia in patients with head and neck cancer. Lancet 2004, 363(9402):80. [author reply 81-2].
12. Hedenus M., Adriansson M., San Miguel J., et al. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 2003, 122(3):394-403.
13. Wright J.R., Ung Y.C., Julian J.A., et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 2007, 25(9):1027-1032.
14. Overgaard J., Hoff C., San Hansen H., et al. Randomized study of the importance of novel erythropoiesis stimulating protein (Aranesp) for the effect of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC). The Danish Head and Neck Cancer Group DAHANCA 10 [abstract 6LB]. Eur J Cancer 2007, 7.
15. Smith R.E., Aapro M.S., Ludwig H., et al. Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol 2008, 26(7):1040-1050.
16. Untch M., von Minckwitz G., Konecny G.E., et al. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer-outcome on prognosis. Ann Oncol 2011, 22(9):1999-2006.
17. Thomas G., Ali S., Hoebers F.J., et al. Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0g/dL with erythropoietin vs above 10.0g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer. Gynecol Oncol 2008, 108(2):317-325.
18. Blohmer J.-U., Wurschmidt F., Petry U., et al. Results with sequential adjuvant chemo-radiotherapy with vs without epoetin alfa for patients with high-risk cervical cancer: results of a prospective, randomized, open and controlled AGO- and NOGGO-intergroup study. Ann Oncol 2004, 15(Suppl. 1). [abstract 477PD].
19. Aapro M., Leonard R.C., Barnadas A., et al. Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study. J Clin Oncol 2008, 26(4):592-598.
20. Crawford J., Robert F., Perry M.C., Belani C., Williams D. A randomized trial comparing immediate versus delayed treatment of anemia with once-weekly epoetin alfa in patients with non-small cell lung cancer scheduled to receive first-line chemotherapy. J Thorac Oncol 2007, 2(3):210-220.
21. Engert A., Borchmann P., Fuchs M., Josting A., Haverkamp H., Diehl V. A prospectively randomized placebo-controlled trial of epoetin-α in patients with advanced-stage Hodgkin lymphoma: final analysis of the GHSG HD15-EPO trial. Blood 2008, 112. [abstract 2598].
22. Grote T., Yeilding A.L., Castillo R., et al. Efficacy and safety analysis of epoetin alfa in patients with small-cell lung cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2005, 23(36):9377-9386.
23. Moebus V., Lueck H., Thomssen C., et al. The impact of epoetin-alpha on anemia, red blood cell (RBC) transfusions, and survival in breast cancer patients (pts) treated with dose-dense sequential chemotherapy: mature results of an AGO phase III study (ETC trial). Proc Am Soc Clin Oncol 2007, 25(18 Suppl.):569.
24. Pirker R., Ramlau R.A., Schuette W., et al. Safety and efficacy of darbepoetin alpha in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide. J Clin Oncol 2008, 26(14):2342-2349.
25. Vansteenkiste J., Pirker R., Massuti B., et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002, 94(16):1211-1220.
26. Witzig T.E., Silberstein P.T., Loprinzi C.L., et al. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 2005, 23(12):2606-2617.
27. Seidenfeld J., Piper M., Bohlius J. Comparative effectiveness of epoetin and darbepoetin for managing anemia in patients undergoing cancer treatment. AHRQ Comparative Effectiveness Reviews 2006, 3. http://www.ncbi.nlm.nih.gov/books/NBK42982/pdf/TOC.pdf.
28. Wilson J., Yao G.L., Raftery J., et al. A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment. Health Technol Assess 2007, 11(13):1-202. iii-iv.
29. Paladini L., Clark O., Clark L., Engel T., Faleiros E. Erythropoiesis Stimulating Agents (ESA) for the treatment of chemotherapy induced anemia in patients with hemoglobin levels (Hb)<11g/Dl-a systematic review and meta-analysis. Blood 2008, 112. [abstract 1305].
30. Bohlius J., Langensiepen S., Schwarzer G., et al. Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J Natl Cancer Inst 2005, 97(7):489-498.
31. Bohlius J., Wilson J., Seidenfeld J., et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006, 98(10):708-714.
32. Bohlius J., Schmidlin K., Brillant C., et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 2009, 373(9674):1532-1542.
33. Glaspy J., Crawford J., Vansteenkiste J., et al. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer 2010, 102(2):301-315.
34. Mittelman M., Neumann D., Peled A., Kanter P., Haran-Ghera N. Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models. Proc Natl Acad Sci U S A 2001, 98(9):5181-5186.
35. Mittelman M., Zeidman A., Kanter P., et al. Erythropoietin has an anti-myeloma effect - a hypothesis based on a clinical observation supported by animal studies. Eur J Haematol 2004, 72(3):155-165.
36. Baz R., Walker E., Choueiri T.K., et al. Recombinant human erythropoietin is associated with increased overall survival in patients with multiple myeloma. Acta Haematol 2007, 117(3):162-167.
37. Jadersten M., Malcovati L., Dybedal I., et al. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol 2008, 26(21):3607-3613.
38. Littlewood T.J., Bajetta E., Nortier J.W., Vercammen E., Rapoport B. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001, 19(11):2865-2874.
39. Drueke T.B., Locatelli F., Clyne N., et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006, 355(20):2071-2084.
40. Singh A.K., Szczech L., Tang K.L., et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006, 355(20):2085-2098.
41. Besarab A., Goodkin D.A., Nissenson A.R. The normal hematocrit study-follow-up. N Engl J Med 2008, 358(4):433-434.
42. Szczech L.A., Barnhart H.X., Inrig J.K., et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 2008, 74(6):791-798.
43. Goodkin D.A. The normal hematocrit cardiac trial revisited. Semin Dial 2009, 22(5):495-502.
44. Pfeffer M.A., Burdmann E.A., Chen C.Y., et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009, 361(21):2019-2032.
45. Nilsson-Ehle H., Birgegard G., Samuelsson J., et al. Quality of life, physical function and MRI T2* in elderly low-risk MDS patients treated to a haemoglobin level of >/=120g/L with darbepoetin alfa +/- filgrastim or erythrocyte transfusions. Eur J Haematol 2011, 87(3):244-252.
46. Elliott S., Busse L., Bass M.B., et al. Anti-Epo receptor antibodies do not predict Epo receptor expression. Blood 2006, 107(5):1892-1895.
47. Fandrey J. Erythropoietin receptors on tumor cells: what do they mean?. Oncologist 2008, 13(Suppl. 3):16-20.
48. LaMontagne K.R., Butler J., Marshall D.J., et al. Recombinant epoetins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models. Mol Cancer Ther 2006, 5(2):347-355.
49. Osterborg A., Aapro M., Cornes P., Haselbeck A., Hayward C.R., Jelkmann W. Preclinical studies of erythropoietin receptor expression in tumour cells: impact on clinical use of erythropoietic proteins to correct cancer-related anaemia. Eur J Cancer 2007, 43(3):510-519.
50. Longmore G.D. Do cancer cells express functional erythropoietin receptors?. N Engl J Med 2007, 356(24):2447.
51. Sinclair A.M., Coxon A., McCaffery I., et al. Functional erythropoietin receptor is undetectable in endothelial, cardiac, neuronal, and renal cells. Blood 2010, 115(21):4264-4272.
52. Swift S., Ellison A.R., Kassner P., et al. Absence of functional EpoR expression in human tumor cell lines. Blood 2010, 115(21):4254-4263.
53. Jelkmann W. Erythropoietin: back to basics. Blood 2010, 115(21):4151-4152.
54. Continuing reassessment of the risks of erythropoiesis-stimulating agents (ESAs) administered for the treatment of anemia associated with cancer chemotherapy. US Food and Drug Administration. FDA briefing document, Oncologic Drugs Advisory Committee. 2007; http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4301b2-02-FDA.pdf.
55. Rizzo J.D., Brouwers M., Hurley P., et al. American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood 2010, 116(20):4045-4059.